Cancer Immunology, Immunotherapy

, Volume 53, Issue 2, pp 64–72

Derangement of immune responses by myeloid suppressor cells

Authors

  • Paolo Serafini
    • Department of Oncology and Surgical Sciences, Oncology SectionAzienda Ospedaliera
  • Carmela De Santo
    • Department of Oncology and Surgical Sciences, Oncology SectionAzienda Ospedaliera
  • Ilaria Marigo
    • Department of Oncology and Surgical Sciences, Oncology SectionAzienda Ospedaliera
  • Sara Cingarlini
    • Department of Oncology and Surgical Sciences, Oncology SectionAzienda Ospedaliera
  • Luigi Dolcetti
    • Department of Oncology and Surgical Sciences, Oncology SectionAzienda Ospedaliera
  • Giovanna Gallina
    • Department of Oncology and Surgical Sciences, Oncology SectionAzienda Ospedaliera
  • Paola Zanovello
    • Department of Oncology and Surgical Sciences, Oncology SectionAzienda Ospedaliera
    • Department of Oncology and Surgical Sciences, Oncology SectionAzienda Ospedaliera
Symposium in Writing

DOI: 10.1007/s00262-003-0443-2

Cite this article as:
Serafini, P., De Santo, C., Marigo, I. et al. Cancer Immunol Immunother (2004) 53: 64. doi:10.1007/s00262-003-0443-2

Abstract

In tumor-bearing mice and cancer patients, tumor progression is often associated with altered hematopoiesis leading to the accumulation of myeloid cells. Extensive studies in preclinical models indicate that these cells share the CD11b and the Gr-1 markers, possess a mixed mature-immature myeloid phenotype, and are responsible for the induction of T-cell dysfunctions, both tumor-specific and nonspecific. Moreover, CD11b+Gr-1+ myeloid cells are described under different unrelated situations associated with temporary impairment of the T-lymphocyte reactivity. This review examines recent findings on the nature, properties, and mechanisms of action of these myeloid suppressor cells (MSCs).

Copyright information

© Springer-Verlag 2003